Dr. Someit Sidhu, Chairman and Chief Executive Officer

Dr. Someit Sidhu is a serial biotech entrepreneur and strategy consultant with broad expertise across the life sciences industry. He has founded and led several healthcare companies, most recently serving as CEO and director of Khanda Therapeutics. Earlier in his career, Dr. Sidhu founded a biotech that was sold to Roivant Sciences. He also co-founded and is CEO of Izana Bioscience and co-founded Pathios Therapeutics. Dr. Sidhu previously served as CEO and a director of JATT Acquisition Corp from its inception until its business combination with Zura Bio in March 2023, where he then served as Chief Executive Officer until April 2024 and Director until May 2026. He also launched JATT II Acquisition, which merged with Talawar Therapeutics in June 2026. Prior to these ventures, he advised major international pharmaceutical companies as a management consultant at McKinsey & Company, focusing on Pharmaceutical R&D and Portfolio Strategy.

Nicholas Fernandez, Chief Financial Officer

Mr. Nicholas Fernandez brings over 20 years of experience across operations, accounting, and finance. He formerly served as Chief Operating Officer and Chief Financial Officer of Athanor Capital from December 2019 to December 2025. Prior to that, he was the Chief Financial Officer of the Asset Management and Alternative Investments Divisions of Jefferies LLC. Mr. Fernandez also served as a director of Iris Acquisition Corp and has been a director of Liminatus Pharma, Inc. since April 2025.

Verender S. Badial, Director

Mr. Verender S. Badial possesses extensive capital markets expertise, having contributed to 48 public market deals. He served as CFO of Zura Bio and was a Co-Founder and CFO of JATT Acquisition Corp. His prior experience includes serving as a Managing Director in Equity Capital Markets at Societe Generale and ABN AMRO Rothschild, and he is also the Founder of Cryfield Investments and ME Asset Management. He has served as a director of JATT II Acquisition Corp since April 2026.

Dr. Arjun Goyal, Director

Dr. Arjun Goyal is the Founder and Managing Partner of Vianti Capital, a venture firm with a strong track record and multiple investments acquired by larger pharmaceutical companies. He serves as a Board Member of Centessa Pharmaceuticals and is a Co-Founder of Vida Ventures, which has been involved in $4 billion in mergers and acquisitions. Dr. Goyal previously served as a Director of Scorpion Therapeutics, Halda Therapeutics, Third Arc Bio, Quanta Therapeutics, and Alterome Therapeutics. He has also served as a director of JATT II Acquisition Corp since April 2026.

Jonathon Kluft, Director

Jonathon Kluft serves as a Director for JATT III Acquisition Corp.

The key risks for Jatt III Acquisition (symbol: JTTT) primarily stem from its nature as a Special Purpose Acquisition Company (SPAC), which is a "blank check company" with no active operations of its own. Its business model relies entirely on identifying and completing a business combination.

1. Inability to Complete a Business Combination: The most significant risk for Jatt III Acquisition is its potential failure to identify and complete a suitable merger, share exchange, asset acquisition, or similar business combination within a prescribed timeframe. The company has not yet identified a target business. If it fails to complete an acquisition, it will be forced to liquidate and return the funds held in trust to its public shareholders, which could result in shareholders losing the value of their warrants and potentially the time value of their investment.
2. Reliance on Management's Ability to Identify and Execute an Acquisition: Jatt III Acquisition has no operating history or established business. Its success is entirely dependent on the ability of its management team, led by CEO and Chairman Someit Sidhu, to identify, evaluate, and successfully complete a business combination, specifically within the healthcare and life sciences sectors. There is no guarantee that the management will find a suitable target or be able to successfully negotiate and close a transaction on favorable terms, or at all.
3. Competition for Acquisition Targets: Jatt III Acquisition faces intense competition from other SPACs, private equity firms, and strategic buyers for attractive acquisition targets. This competitive landscape could make it difficult for the company to secure a desirable business combination, potentially leading to increased acquisition costs or the inability to find a suitable target altogether.

As a Special Purpose Acquisition Company (SPAC), Jatt III Acquisition (JTTT) currently has no operating business or revenue. Its future revenue growth is entirely dependent on successfully completing a business combination with a target company. Based on the company's stated focus, the expected drivers of future revenue growth over the next 2-3 years will be derived from the characteristics and performance of the entity it eventually acquires.

Here are 3-5 expected drivers of future revenue growth for Jatt III Acquisition:

1. Successful Business Combination: The most critical driver is the successful identification and completion of a merger or acquisition with an operating business. Until a target company is acquired, Jatt III Acquisition will not generate any revenue. The timing and terms of this combination will lay the foundation for all subsequent revenue generation.
2. Growth of Acquired Company's Existing Products/Services: Once Jatt III Acquisition merges with a target, the revenue growth will be driven by the existing product portfolio and services of the acquired entity. The SPAC specifically intends to focus on healthcare and life sciences businesses, with an emphasis on biotechnology, suggesting revenue growth could come from increased sales of existing therapeutic products, diagnostic services, or scientific platforms.
3. Launch of New Products or Services by the Acquired Company: Future revenue growth will also be significantly influenced by the acquired company's ability to develop and launch new, innovative products or services. Jatt III Acquisition has indicated a preference for businesses utilizing data-driven approaches, including machine learning and computational biology, to improve therapeutic discovery and development, implying a pipeline of potential new offerings that could drive growth.
4. Expansion into New Markets by the Acquired Company: Post-acquisition, the growth strategy of the combined entity may involve expanding the acquired company's presence into new geographic regions or new therapeutic areas. This market expansion would introduce existing or new products/services to a broader customer base, thereby contributing to revenue growth.
5. Strategic Synergies and Operational Enhancements: The management team of Jatt III Acquisition brings experience in building, operating, and investing in the life sciences sector. This expertise is expected to benefit the acquired company by accelerating development, executing strategic transactions, and enhancing visibility with investors and partners, which could lead to improved operational efficiency and increased revenue generation post-combination.

Share Issuance

• JATT III Acquisition Corp priced its initial public offering (IPO) of 6,000,000 ordinary shares at $10.00 per share.
• The offering aimed to raise gross proceeds of $60 million.
• The company granted the underwriters a 45-day option to purchase up to 900,000 additional ordinary shares at the IPO price to cover over-allotments.

Inbound Investments

• The company secured $60 million in gross proceeds from its initial public offering.
• JATT III Acquisition Corp is a blank check company formed for the purpose of entering into a business combination with one or more businesses.
• The SPAC intends to focus its search on healthcare and healthcare-related businesses, particularly in biotechnology and broader life sciences.